Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 48

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 48
---
We estimate that the net
proceeds of the Company Offering will be approximately $9,190,000 based on the assumed combined public offering price of $ 2.19
per share and accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August 21,
2025), after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from
the exercise of the warrants. Each $0.10 increase (decrease) in the assumed combined public offering price of $ 2.19 per share and
accompanying warrant would increase (decrease) the net proceeds to us from this offering by approximately $433,000, assuming the number
of shares and warrants offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the placement
agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares of our common stock and
warrants we are offering. Each 1.0 million share increase (decrease) in the number of shares sold in this offering would increase
(decrease) the expected net proceeds of the offering to us by approximately $2.1 million, assuming that the assumed combined public
offering price per share and accompanying warrant remains the same.

We currently intend to use the
net proceeds of the Company Offering for general corporate purposes, which will include research and development expenses, clinical trial
expenses, capital expenditures and working capital. We may also use a portion of the net proceeds from the Company Offering to in-license,
acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current plans, commitments or obligations
to do so. Pending use of the net proceeds, we intend to invest the proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments.

We cannot currently allocate specific
percentages of the net proceeds to us from the Company Offering that we may use for the purposes specified above and our management will
have broad discretion in the allocation of the net proceeds.

| 27 |

<div align='center'>SELLING SECURITYHOLDERS</div>

This prospectus covers the resale
or other disposition by the Selling Securityholders identified in the table below of up to 1,550,000 shares of common stock issuable upon
the exercise Inducement Warrants.

We are registering the shares
of common stock underlying